Navigation Links
Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S.
Date:6/13/2011

TOKYO, June 14, 2011 /PRNewswire/ -- Mitsubishi Chemical Medience Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) premarketing notification clearance to the PATHFAST® cTnI-II (cardiac Troponin I) diagnostic test, clearing the way for its sale in the United States. The test is designed to be used with the PATHFAST analysis system, a unique, self-contained, bench-top chemi-luminescence immunoanalyzer that rapidly measures concentrations of emergency biomarkers from a single whole blood sample.

The PATHFAST cTnI-II test determines the quantity of cardiac troponin I, a protein that is integral to cardiac muscle contraction, which is elevated in the bloodstream after damage to the myocardium (the middle and thickest layer of the heart wall).(1),(2) Due to its absolute coronary specificity and high sensitivity, cardiac troponin I is considered the preferred biomarker for diagnosing cardiac muscle damage, particularly following a heart attack.

"We are pleased that the FDA has recognized the utility of the PATHFAST system for measuring levels of cardiac troponin I in whole blood, and are confident the test will be widely accepted in the U.S. market, in accordance with international guidelines," commented Dr. Toshihiko Yoshitomi, President and CEO of Mitsubishi Chemical Medience. "Today's news is also an important step in supporting our ongoing negotiations to secure a strategic distribution partnership to launch the PATHFAST product line in the U.S. by early 2012."  

The 510(k) clearance of the PATHFAST cTnI-II test completes the cardiovascular product line of the PATHFAST analysis system, which also includes tests to determine quantities of N-terminal pro brain natriuretic peptide (NT-proBNP), D-Dimer, myoglobin, creatinine kinase (CK)-MB, and high-sensitivity C-reactive protein (hsCRP). With its whole blood use capability, the PATHFAST system eliminates the need for centrifugation of the specimen preparation, and can be used with either plasma or serum. The system has a 17-minute turn around time, a feature that can significantly reduce testing time, which can be a key consideration in a clinical laboratory or point-of-care (POC) setting.  

Mitsubishi Chemical Medience and Mitsubishi Chemical Europe have sold more than 1,000 units of the PATHFAST system in Asia, Europe, and Latin America. The PATHFAST cTnI-II test is considered "guideline acceptable" by virtue of its minimal imprecision, as measured by a coefficient of variance (CV) of less than or equal to 10% at the 99th percentile.(3) By generating precise, accurate, and rapid results, the PATHFAST cTnI-II test is expected to enhance patient safety by streamlining coordination between emergency POC and central laboratories. It may be particularly useful in the emergency room (ER) setting, as well as in satellite laboratories, physician laboratories, and central laboratories.

About Mitsubishi Chemical Medience Corporation

Mitsubishi Chemical Medience Corporation is a member of the Mitsubishi Chemical Holdings Corporation Group, which is headquartered in Tokyo, Japan. Mitsubishi Chemical Medience is the first company in Japan to establish a business style that combines clinical and diagnostic laboratory testing services with in vitro diagnostics (IVD) and pharmaceutical development support. One of Mitsubishi Chemical Medience's primary business areas is their IVD business, which includes the development, sale, export, and import of in vitro diagnostic reagents and instruments. Mitsubishi Chemical Medience's globally accepted PATHFAST system, a rapid point-of-care immunochemistry analyzer, has been exported to more than 40 countries. Throughout almost five decades of IVD business, customers in various chemical and diagnostic industry segments have come to trust and rely on Mitsubishi Chemical Medience's competence and strength, as represented by the superior quality of their products and customized solutions.

(1) McGraw-Hill Concise Dictionary of Modern Medicine. New York, NY: The McGraw-Hill Companies, Inc., 2002. http://medical-dictionary.thefreedictionary.com/troponin+I.  Accessed June 3, 2011.

(2) Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. Philadelphia, PA: Saunders, 2003.  http://medical-dictionary.thefreedictionary.com/myocardium.  Accessed June 6, 2011.

(3) Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clinical Chemistry 2009;55(7):1303-1306.


'/>"/>
SOURCE Mitsubishi Chemical Medience Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders
2. Reportlinker Adds The Global Pharmaceutical Fine Chemicals Market Outlook to 2015
3. AMPAC Fine Chemicals Adds New Capabilities for Clinical Programs
4. Ampac Fine Chemicals President Aslam Malik Joins SOCMAs Board of Governors; Industry Veteran Adds Significant Experience to Board
5. FDA Approves Pediatric Use of Chemical Poisoning Treatment
6. Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society
7. Multiple Chemical Sensitivities Are Real
8. ChemImages Raman Chemical Imaging Used for Ingredient-Specific Particle Sizing for Inhalation Product Development
9. AMPAC Fine Chemicals Partners With Inabata & Co., Ltd. of Japan
10. New ionator EXP(TM) and ionator HOM(TM) Kill Swine Flu Without Use of Chemicals
11. Sigma-Aldrich Becomes the Sole U.S. and Canada Distributor of Kromasil(R) HPLC Columns Through Agreement With Eka Chemicals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Research and Markets has announced the addition of the ... (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab (Hospital, ... HIV/AIDS etc.), Forecast to 2022" report to their offering. ... US ... clinical lab testing, which has evolved as a major source ...
(Date:1/21/2017)... Research and Markets has announced the addition ... Technology, Route Of Administration, End User - Forecast to 2025" ... ... at a CAGR of around 7.8% over the next decade to ... report analyzes the global markets for Advanced Drug Delivery across all ...
(Date:1/20/2017)... YORK , January 20, 2017 ... Inc. (NASDAQ: SGYP ), Novo Nordisk A/S (NYSE: ... SCMP ), and Pernix Therapeutics Holdings Inc. (NASDAQ: ... fell on Thursday, January 19 th , 2017, finishing near ... Health Care Index dropped over 0.7%, while shares of health ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... The ... Dr. Dan Holtzclaw in media for its creos™ line of bone regenerative products. ... Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a variety ...
(Date:1/20/2017)... ... ... Pastor and Overseer at The House of Yahweh has posted a new publication this week ... is a time like no other and society needs to understand the only way to ... not want to sound like an old bible beater because religion has a bad rap ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an American ... announced it had a successful January ECRM Trade Show in Hilton Head, SC. ... which allows it to provide its products to all clients at reasonable prices. At ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company ... bodybuilding supplements, announced it attended the January ECRM trade show in Hilton Head, SC. ... scientist who was determined to create a line of products that would elevate her ...
(Date:1/20/2017)... ... 20, 2017 , ... Vitamin Well has launched two new ... have been produced in collaboration with Zlatan Ibrahimovic and have been developed to ... a successful launch in Sweden last year, the next generation sports drinks VW+001 ...
Breaking Medicine News(10 mins):